These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39089574)

  • 1. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
    García-Pavía P; García-Pinilla JM; Lozano-Bahamonde A; Yun S; García-Quintana A; Gavira-Gómez JJ; Aibar-Arregui MÁ; Barge-Caballero G; Núñez Villota J; Bernal L; Tarilonte P
    Rev Esp Cardiol (Engl Ed); 2024 Jul; ():. PubMed ID: 39089574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An echo score raises the suspicion of cardiac amyloidosis in Chinese with heart failure with preserved ejection fraction.
    Yang H; Li R; Ma F; Wei Y; Liu Y; Sun Y; He X; Zeng H; Yan J; Wang DW; Wang H
    ESC Heart Fail; 2022 Dec; 9(6):4280-4290. PubMed ID: 36128643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of transthyretin cardiac amyloidosis in elderly patients diagnosed with heart failure.
    Jaramillo-Hidalgo J; Quezada-Feijoó M; Ramos M; Toro R; Gómez-Pavón J; Ayala-Muñoz R
    Rev Esp Geriatr Gerontol; 2023; 58(1):8-14. PubMed ID: 36404188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
    Klaassen SH; van Veldhuisen DJ; Nienhuis H; van den Berg MP; Hazenberg BP; van der Meer P
    Card Fail Rev; 2020 Mar; 6():e21. PubMed ID: 32944291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis.
    Alonso M; Neicheril RK; Manla Y; McDonald ML; Sanchez A; Lafave G; Seijo De Armas Y; Camargo AL; Uppal D; Wolinsky D; Thakkar-Rivera N; Velez M; Baran DA; Estep JD; Snipelisky D
    ESC Heart Fail; 2024 Aug; ():. PubMed ID: 39180423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
    Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
    JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    Davies DR; Redfield MM; Scott CG; Minamisawa M; Grogan M; Dispenzieri A; Chareonthaitawee P; Shah AM; Shah SJ; Wehbe RM; Solomon SD; Reddy YNV; Borlaug BA; AbouEzzeddine OF
    JAMA Cardiol; 2022 Oct; 7(10):1036-1044. PubMed ID: 36069809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical differences between transthyretin cardiac amyloidosis and hypertensive heart disease.
    Gallo-Fernández I; López-Aguilera J; González-Manzanares R; Pericet-Rodriguez C; Carmona-Rico MJ; Perea-Armijo J; Castillo-Domínguez JC; Anguita-Sánchez M;
    Med Clin (Barc); 2024 Mar; 162(5):205-212. PubMed ID: 38044190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center.
    López-Sainz Á; Hernandez-Hernandez A; Gonzalez-Lopez E; Domínguez F; Restrepo-Cordoba MA; Cobo-Marcos M; Gómez-Bueno M; Hernandez-Perez FJ; Oteo JF; Mirelis JG; Cavero MA; Moñivas V; Mingo Santos S; de Haro-Del Moral FJ; Krsnik I; Salas C; Bornstein B; Briceño A; López JA; Vázquez J; Alonso-Pulpón L; Segovia J; Garcia-Pavia P
    Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):149-158. PubMed ID: 32317158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
    JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
    Lau ATC; DiDomenico RJ; Kim K
    Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.
    Hahn VS; Yanek LR; Vaishnav J; Ying W; Vaidya D; Lee YZJ; Riley SJ; Subramanya V; Brown EE; Hopkins CD; Ononogbu S; Perzel Mandell K; Halushka MK; Steenbergen C; Rosenberg AZ; Tedford RJ; Judge DP; Shah SJ; Russell SD; Kass DA; Sharma K
    JACC Heart Fail; 2020 Sep; 8(9):712-724. PubMed ID: 32653448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevalence of transthyretin cardiac amyloidosis in patients hospitalized for heart failure with preserved ejection fraction and septal thickness].
    Decotto S; Fernández Villar G; Llamedo MC; Villanueva E; Pérez De Arenaza D; Lucas L; Del Castillo S; Rossi E; Belziti C; Pizarro R
    Medicina (B Aires); 2024; 84(5):823-830. PubMed ID: 39399922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis.
    Enríquez-Vázquez D; Gómez-Martín C; Barge-Caballero G; Barge-Caballero E; López-Pérez M; Bilbao-Quesada R; González-Babarro E; Gómez-Otero I; López-López A; Gutiérrez-Feijoo M; Varela-Román A; Crespo-Leiro MG
    Med Clin (Barc); 2024 Apr; 162(7):e1-e7. PubMed ID: 38423944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
    Papathanasiou M; Jakstaite AM; Oubari S; Siebermair J; Wakili R; Hoffmann J; Carpinteiro A; Hagenacker T; Thimm A; Rischpler C; Kessler L; Rassaf T; Luedike P
    ESC Heart Fail; 2022 Jun; 9(3):1740-1748. PubMed ID: 35178887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study).
    Poterucha TJ; Kurian D; Raiszadeh F; Teruya S; Elias P; Kogan R; Chiuzan C; Einstein AJ; Ruberg FL; Maurer MS
    Am J Cardiol; 2022 Aug; 177():116-120. PubMed ID: 35705430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.
    Cipriani A; De Michieli L; Porcari A; Licchelli L; Sinigiani G; Tini G; Zampieri M; Sessarego E; Argirò A; Fumagalli C; De Gaspari M; Licordari R; Russo D; Di Bella G; Perfetto F; Autore C; Musumeci B; Canepa M; Merlo M; Sinagra G; Gregori D; Iliceto S; Perazzolo Marra M; Cappelli F; Rapezzi C
    JACC CardioOncol; 2022 Nov; 4(4):458-470. PubMed ID: 36444225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy.
    Devesa A; Camblor Blasco A; Pello Lázaro AM; Askari E; Lapeña G; Gómez Talavera S; Taibo Urquía M; Rodríguez Olleros C; Tuñón J; Ibáñez B; Aceña Á
    ESC Heart Fail; 2021 Aug; 8(4):2856-2865. PubMed ID: 33963812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors.
    Barge-Caballero G; Vázquez-García R; Barge-Caballero E; Couto-Mallón D; Paniagua-Martín MJ; Barriales-Villa R; Piñón-Esteban P; Bouzas-Mosquera A; Pombo-Otero J; Debén-Ariznavarreta G; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Med Clin (Barc); 2021 Apr; 156(8):369-378. PubMed ID: 32591181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.